Personalized Medicine...the aspiration that personalized medicine can and will be the paradigm for...

Conference Program

Personalized Medicine: A Value Proposition

A Conference Hosted By

HARVARD MEDICAL SCHOOL – PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

HARVARD BUSINESSSCHOOL

A CONFERENCE TO FOCUS ON RECOGNIZING

THE VALUE OF PERSONALIZED MEDICINE

November 12-14, 2008 Joseph B. Martin Conference Center at Harvard Medical School, Boston

HIGHLIGHTS FROM PAST CONFERENCES

3

November 12, 2008

Dear Colleague,

Welcome to the 2008 conference Personalized Medicine: A ValueProposition. This is the fourth such annual gathering and the HarvardMedical School-Partners HealthCare Center for Genetics and Genomicsis pleased again to have Harvard Business School as its co-host and thecollaboration of the Personalized Medicine Coalition for this importantmeeting.

In our current economic circumstances, where healthcare issues arebeing vigorously debated, it is very important to find strategies toimprove the quality of healthcare without placing extraordinary burdens

on society. I have argued for many years that the practice of personalized medicine cancontribute positively to achieving this objective. The ever increasing pace of genetic andgenomic discoveries, the rapid reduction in costs for such activities as whole genomesequencing and the rate at which the knowledge is being translated into the clinic reinforcethe aspiration that personalized medicine can and will be the paradigm for patient care.

For personalized medicine to be a reality it is important that we can demonstrate its value.The value proposition of personalized medicine is different for different sectors of thecommunity. Nevertheless, patients; physicians; scientists; pharmaceutical, diagnostic, andinformation technology companies; insurers; venture capital and other funding sources; andgovernment agencies all have to find a common language and a common purpose inimplementing personalized medicine. We also must recognize that personalized medicine hasno regional or national boundaries – it is equally applicable to all individuals in all nations.Reaching those points of progress are the theme and the goal of this year’s conference.

The cause of personalized medicine has enjoyed a significant boost in recent years throughthe active advocacy of Secretary Michael Leavitt and several of his colleagues at the U.S.Department of Health and Human Services and in the focused consideration of thePresident’s Council of Advisors on Science and Technology. Both will play prominent rolesin this year’s conference, underlining the essential values that personalized medicine offersand providing substantive context for all our discussions.

I am deeply grateful to the members of our organizing committee, our speakers and panelists, my staff, and the generous sponsors, all of whose involvement is critical to thesuccess of our meeting.

Sincerely,

Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics and Professor of MedicineHarvard Medical SchoolScientific Director EmeritusHarvard Medical School-Partners HealthCare Center for Genetics and Genomics

SponsorsThis conference is organized by the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics and Harvard Business School in collaboration

with the Personalized Medicine Coalition. It is made possible by the generous support of our sponsors.

PLATINUM

GOLD

SILVER

BRONZE

CONTRIBUTING SPONSOR

H A R V A R D M E D I C A L S C H O O L - P A R T N E R S H E A L T H C A R E

C E N T E R F O R G E N E T I C S A N D G E N O M I C S

4

5

Raju Kucherlapati, Ph.D., ChairPaul C. Cabot Professor of Genetics,Professor of MedicineHarvard Medical SchoolScientific Director EmeritusHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

Edward Abrahams, Ph.D.Executive DirectorPersonalized Medicine Coalition

Joanne C. Armstrong, M.D.Senior Medical Director for Women'sHealth and Clinical Lead for GenomicsAetna, Inc.

Mara G. AspinallSenior Advisor, Genzyme CorporationDana-Farber Cancer Institute

Keith F. Batchelder, M.D.CEO and FounderGenomic Healthcare Strategies

M. Kathleen Behrens, Ph.D.General Partner, RS InvestmentsMember, President's Council of Advisorson Science and Technology (PCAST)

Nadine Cohen, Ph.D.Head of Pharmacogenomics and SeniorResearch FellowJohnson & Johnson PharmaceuticalResearch and Development LLC

Peter DworkinVice President, Investor Relations andCorporate CommunicationsApplera Corporation

Richard G. Hamermesh, D.B.A.MBA Class of 1961 Professor ofManagement PracticeFaculty Chair, HBS Healthcare InitiativeHarvard Business School

Regina E. Herzlinger, D.B.A.Nancy R. McPherson Professor ofBusiness AdministrationHarvard Business School

Marcia A. KeanChief Executive OfficerFeinstein Kean Healthcare

Nick LittlefieldPartnerFoley Hoag LLP

Jeffrey D. MillerVice President, Worldwide Health andLife Sciences/Public Sector TechnologySolutions GroupHewlett-Packard Company

Thomas J. MillerChief Executive Officer, DivisionWorkflow & SolutionsSiemens AG, Sector Healthcare

Samuel R. Nussbaum, M.D.Executive Vice President and ChiefMedical OfficerWellpoint, Inc.

Eiry W. Roberts, MB (Hons) BS MRCP FFPMVice President, Transitional PhaseDevelopmentEli Lilly and Company

Hakan Sakul, Ph.D.Senior Director and Global Head ofDiagnostics, Molecular Medicine Group,Worldwide DevelopmentPfizer Global Research & Development

Robert C. WellsPartnerHealthFutures, LLC

IT Symposium Organizing Committee

Raju Kucherlapati, Ph.D., ChairPaul C. Cabot Professor of Genetics,Professor of MedicineHarvard Medical SchoolScientific Director EmeritusHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

Samuel J. AronsonExecutive Director of InformationTechnologyHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

David J. Brailer, M.D., Ph.D.Chairman, Health Evolution Partners

John P. Glaser, Ph.D.Vice President and Chief InformationOfficerPartners HealthCare

Committee Members Ex Officio

Alfred A. Blum, Jr.Chief Development OfficerHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

Janice LarsonDevelopment AssociateHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

Rebecca RehmProgram AssociateHarvard Medical School-PartnersHealthCare Center for Genetics andGenomics

Conference Organizing Committee

Harvard-Partners Center forGenetics and GenomicsLabs at 65 LandsdowneStreet, Cambridge



6

Conference Program

Information Technology & Personalized Medicine SymposiumWednesday, November 12, 2008

12:00 p.m. Registration & Refreshments All talks and sessions will take place in theAmphitheater unless otherwise noted

1:00 p.m. Welcome Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine,Harvard Medical School, Scientific Director Emeritus, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics

1:05 p.m. Keynote: Realizing Value in David J. Brailer, M.D., Ph.D.Personalized Medicine Chairman, Health Evolution Partners

Introducer: Diane KeoghCorporate Director for Research Computing, Partners HealthCare

1:40 p.m. Panel I: Genetics in the Moderator: Jeffrey D. MillerHealthcare Enterprise Vice President, Worldwide Health and Life Sciences/Public

Sector Technology Solutions Group, Hewlett-Packard Company

Neil de CrescenzoSenior Vice President and General Manager, Healthcare and LifeSciences, Oracle Corp.

Janet DillioneChief Executive Officer, Health Services, Siemens Medical Solutions

John P. Glaser, Ph.D.Vice President and Chief Information Officer, Partners HealthCare

Eiry W. Roberts, MB (Hons) BS MRCP FFPMVice President, Transitional Phase Development, Eli Lilly and Company

2:40 p.m. Break & Refreshments

7

3:10 p.m. Panel II: Business Outlook Moderator: Thomas J. MillerChief Executive Officer, Division Workflow & Solutions, Siemens AG, Sector Healthcare

George M. Church, Ph.D.Professor of Genetics, Harvard Medical School, Director, Center for Computational Genetics

James HeywoodChairman and Co-Founder, PatientsLikeMe

Frederick S. Lee, M.D., M.P.H.Product Manager for Personalized Medicine and Genomics,McKesson Corp.

Steven St. Peter, M.D., M.B.A.Managing Director, MPM Capital

4:15 p.m. Panel III: IT in Personalized Moderator: Samuel J. AronsonGenomics Executive Director of Information Technology, Harvard Medical

School-Partners HealthCare Center for Genetics and Genomics

Linda AveyCo-Founder, 23andMe

Jorge CondeCo-Founder and Chief Executive Officer, Knome, Inc.

David P. KingPresident and Chief Executive Officer, Laboratory Corporation ofAmerica

Dietrich A. Stephan, Ph.D.Founder and Chief Science Officer, Navigenics, Inc.

5:15 p.m. Closing Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine,Harvard Medical School, Scientific Director Emeritus, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics

Information Technology & Personalized Medicine SymposiumWednesday, November 12, 2008 continued



8

7:30 a.m. Registration & Continental Breakfast

8:45 a.m. Welcome Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine,Harvard Medical School, Scientific Director Emeritus, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics

9:00 a.m. Keynote: The Innovator's Clayton M. Christensen, D.B.A.Prescription: A Disruptive Solution Robert and Jane Cizik Professor of Business Administration,to our Health Care Crisis Harvard Business School

Introducer: Sandra Glucksmann, Ph.D.Senior Vice President of Research and Business Operations,Tempo Pharmaceuticals

Keynote: Personalized Richard M.J. Bohmer, MBChB, MPHMedicine and Medical Practice MBA Class of 1973 Senior Lecturer of Business Administration,

Harvard Business School

Introducer: Robert I. Tepper, M.D.Partner, Third Rock Ventures, LLC

Conversation with Moderator: Richard G. Hamermesh, D.B.A.Keynote Speakers MBA Class of 1961 Professor of Management Practice, Faculty

Chair, HBS Healthcare Initiative, Harvard Business School

10:30 a.m. Break & Refreshments

11:15 a.m. Panel Discussion: Introducer: Christine Seidman, M.D.Evidence-Based Medicine Investigator, Howard Hughes Medical Institute, Thomas W.

Smith Professor of Medicine and Genetics, Harvard Medical School, Director, Cardiovascular Genetics Center, Brigham and Women’s Hospital

Moderator: Mason W. Freeman, M.D.Chief, Lipid Metabolism Unit, Massachusetts General Hospital,Harvard Medical School

Mark A. Creager, M.D.Professor of Medicine, Brigham and Women’s Hospital, Harvard Medical School

Felix W. Frueh, Ph.D.Vice President, R&D, Personalized Medicine, Medco Health Solutions, Inc.

Personalized Medicine: A Value PropositionThursday, November 13, 2008

Conference Program

9

continued Panel Discussion: Matthew P. Goetz, M.D.Evidence-Based Medicine Assistant Professor of Oncology, Assistant Professor of

Pharmacology, Mayo Clinic

Peter G. Traber, M.D.President, Chief Executive Officer and Executive Dean, Baylor College of Medicine

12:30 p.m. Break – Transition to Rotunda, Pechet Room and Room 350

1:00 p.m. Luncheon Keynote: The Lord Naren Patel, MB, ChBA Report on the Enquiry Member, House of Lordson Genomic Medicine,United Kingdom Introducer: Joanne C. Armstrong, M.D.

Senior Medical Director for Women’s Health and Clinical Lead for Genomics, Aetna, Inc.

2:00 p.m. Table Discussions Facilitators:

Robert C. WellsPartner, HealthFutures, LLC

Harry GlorikianManaging Partner, Scientia Advisors

Mollie Roth, Esq.Corporate Counsel, Vice President, Business Development,Diaceutics

3:00 p.m. Break – Transition back to Amphitheater

3:15 p.m. Keynote: Progressing Personalized Aidan C. Power, MB BCh MSc MRCPsychMedicine in Pharma: Vice President & Global Head of Molecular Medicine, Pfizer A Perspective from Pfizer Global Research and Development

Introducer: Nadine Cohen, Ph.D.Head of Pharmacogenomics and Senior Research Fellow,Johnson & Johnson Pharmaceutical Research and Development. LLC

3:45 p.m. Case Studies on Chair: Deborah Dunsire, M.D.Drugs & Treatments President and Chief Executive Officer, Millennium

Pharmaceuticals, Inc. – The Takeda Oncology Company

Mary Del BradyPresident and Chief Executive Officer, RedPath Integrated Pathology, Inc.

David D. Chang, M.D., Ph.D.Vice President Global Development, Hematology/Oncology,Amgen, Inc.

5:00 p.m. Reception – Elements Café

Personalized Medicine: A Value PropositionThursday, November 13, 2008 continued



10

7:15 a.m. Continental Breakfast

8:15 a.m. Keynote: Personalized Health Care: The Honorable Michael O. LeavittA Value Predicate Secretary of Health and Human Services, U.S. Department of

Health and Human Services

Introducer: James J. Mongan, M.D.President and Chief Executive Officer, Partners HealthCare

Personalized Medicine Coalition’s Award Background: Edward Abrahams, Ph.D.Fourth Annual Award for Executive Director, Personalized Medicine CoalitionLeadership in Personalized Medicine Presenter: Mara G. Aspinall

Senior Advisor, Genzyme Corporation, Dana-Farber Cancer Institute

9:15 a.m. Panel Discussion: Moderator: M. Kathleen Behrens, Ph.D.Government & Regulators General Partner, RS Investments, Member, President’s Council of

Advisors on Science and Technology (PCAST)

Arthur A. Daemmrich, Ph.D.Assistant Professor of Business Administration, Harvard Business School

Gregory J. Downing, D.O., Ph.D.Program Director, Personalized Health Care, U.S. Department of Health and Human Services

Lawrence J. Lesko, Ph.D., FCPDirector, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Michael S. Paul, Ph.D.President and Chief Executive Officer, LineaGen

10:30 a.m. Break & Refreshments

Personalized Medicine: A Value PropositionFriday, November 14, 2008

Conference Program

11

11:00 a.m. Panel Discussion: Moderator: Samuel R. Nussbaum, M.D.Reimbursement Executive Vice President, Clinical Health Policy and Chief

Medical Officer, WellPoint, Inc.

Mara G. AspinallSenior Advisor, Genzyme Corporation, Dana-Farber Cancer Institute

Robert S. Epstein, M.D., M.S.Senior Vice President, Medical & Analytical Affairs and Chief Medical Officer, Medco Health Solutions, Inc.

Carol J. McCall, FSA, MAAAVice President, Research and Development, Innovation Center,Humana, Inc.

Margaret Piper, Ph.D., M.P.H.Associate Director, Blue Cross/Blue Shield Association Technology Evaluation Center

12:20 p.m. Town Hall Meeting Facilitators:

Robert C. WellsPartner, HealthFutures, LLC

Harry GlorikianManaging Partner, Scientia Advisors

Mollie Roth, Esq.Corporate Counsel, Vice President, Business Development,Diaceutics

1:20 p.m. Closing Raju Kucherlapati, Ph.D.Paul C. Cabot Professor of Genetics, Professor of Medicine,Harvard Medical School, Scientific Director Emeritus, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics

1:30 p.m. Bag Lunch

Personalized Medicine: A Value PropositionFriday, November 14, 2008 continued



12

Edward Abrahams, Ph.D.Edward Abrahams, Ph.D., Executive Director of thePersonalized Medicine Coalition, a non-profit educationaland advocacy group representing diverse members with a

interest in advancing medical progressthrough the adoption of personalizedmedicine concepts and products, bringsextensive experience in industry, acade-mia, and government to the position. Asformer Executive Director of thePennsylvania Biotechnology Association,Dr. Abrahams managed all aspects ofthe Association, including public advoca-cy, media relations, and educational pro-

grams, tripling its size and revenues in three years. He alsospearheaded the successful effort that led to theCommonwealth of Pennsylvania's investment of $200 mil-lion to commercialize biotechnology in that state.

Previously, Dr. Abrahams had been Assistant VicePresident for Federal Relations at the University ofPennsylvania, and also held a senior administrative positionat Brown University. Before becoming a university adminis-trator, Dr. Abrahams worked seven years for the UnitedStates Congress, including as a legislative assistant toSenator Lloyd Bentsen and as an economist for the JointEconomic Committee under the chairmanship ofCongressman Lee Hamilton. In addition to articles in bothpopular and professional journals, he is the author of TheLyrical left: Randolph Bourne, Alfred Stieglitz and theOrigins of Cultural Radicalism in America.

Joanne Armstrong, M.D., M.P.H.Joanne Armstrong, MD, MPH is a senior medical director atAetna where she leads the areas of women’s health and

genetics. In this role, she is the clinicaland strategic lead for genomic medi-cine-related activities including policydevelopment, clinical program develop-ment and implementation, medical costmanagement efforts, and other activi-ties. Dr. Armstrong is board-certified inobstetrics and gynecology and has addi-tional training in epidemiology and pub-lic health.

Aetna is the nation’s third largest health benefits compa-ny, providing medical benefits for nearly 16 million individu-als and pharmacy benefits for 10 million individuals.

Samuel (Sandy) AronsonSamuel (Sandy) Aronson is the Executive Director of IT ofthe Partners Center for Personalized Genetic Medicine(PCPGM). In this position he oversees the development ofIT infrastructure to support both the PCPGM’s facilities andit’s clinically focused Laboratory for Molecular Medicine.

This includes the development of portal,LIMS and repository systems as well asintegrating these systems with otherPartners clinical infrastructure. Mr.Aronson’s group also actively works withother groups to continuously enhancesupport for genetics in the electronichealth record. Prior to this position, Mr.Aronson held several positions withSapient Corporation, was a Strategic

Consultant for Monitor Company and foundedLearningAction, a web-based training company. Mr.Aronson holds a Masters in Organizational Behavior and aBachelors in Computer Science from Stanford University.He also holds a Masters in Biology from Harvard ExtensionSchool.

Mara G. Aspinall, M.B.A.Mara Aspinall is a biotechnology executive with focus andexperience in oncology, diagnostics and personalized medi-cine. She is currently on sabbatical from Genzyme workingat Harvard Medical School and Dana Farber Cancer Instituteon the implementation of personalized medicine into physi-

cian education, clinical practice andresearch. For the last seven years, Marawas President of Genzyme Genetics, aleading provider of testing and consulta-tive services in the oncology and repro-ductive markets. Genzyme Genetics is abusiness unit of Genzyme Corporation,one of the world's largest biotechnologyfirms with more than 10,000 employeesand $4 billion in revenue.

Under Mara's leadership, Genzyme Genetics set the stan-dard for quality in the industry, while growing the businessat an unprecedented pace. She transformed the business –expanding its scope and market reach to become one ofthe nation’s largest diagnostic laboratories. The divisionsuccessfully completed and integrated four acquisitions,expanded research and development and initiated new pro-grams for community outreach and education.

She is an active member of the Federal Secretary ofHealth and Human Services’ Advisory Commission onGenetics, Health and Society as well as Vice Chairman ofthe Personalized Medicine Coalition. Most recently, she co-authored, “Realizing the Promise of Personalized Medicine”in Harvard Business Review.

Conference Speakers

13

continued

Mara previously served as President of another Genzymedivision, Genzyme Pharmaceuticals. In her four years asPresident, she restructured the business from generic drugmanufacturing to value-added custom production. She builta new international management team that created morethan 25% annual growth.

Mara started her business career at Bain & Company, aninternational strategic consulting firm. Her Masters ofBusiness Administration from Harvard Business School wasenriched with the John P. Stevens Prize for leadership.

Linda AveyLinda has over 20 years of sales and business developmentexperience in the biopharmaceutical industry in San

Francisco, Boston, San Diego, andWashington, D.C. Prior to starting23andMe, she developed translationalresearch collaborations with academicand pharmaceutical partners forAffymetrix and Perlegen Sciences. Lindaalso spent time at Spotfire helping sci-entists understand the power of datavisualization and at Applied Biosystemsduring the early days of the human

genome project. The advent of high density genome-widescanning technologies brought huge potential for signifi-cant discoveries. However, the lack of sufficient funding toenable adequate studies prompted Linda to think of a newresearch model. These ideas led to the formation of23andMe. Her primary interest is the acceleration of per-sonalized medicine, using genetic profiles to target the rightdrug to the right person at the correct dose. Linda graduat-ed from Augustana College with a B.A. in biology.

M. Kathleen Behrens, Ph.D.Dr. Behrens presently serves as a member of the President’sCouncil of Advisors on Science and Technology (PCAST), arole in which she has served since 2001. She was a direc-tor of the Board on Science, Technology and Economic

Policy (STEP) for the National ResearchCouncil from 1997-2005, at which timeshe also participated as a member ofthe Institute of Medicine Committee onNew Approaches to Early Detection andDiagnosis of Breast Cancer. Kathy was adirector of the National Venture CapitalAssociation from 1993 to 2000, alsoserving as President of the NVCA fromMay, 1998 through April, 1999,

Chairman from May 1999 through September, 1999 andPast Chairman from October 1999 through April, 2000. Dr.Behrens was a Trustee of the University of California, Davis,Foundation from 1996-2001 and also is a member of theAdvisory Committee for the J. David Gladstone Institutes.Kathy holds a Ph.D. in Microbiology from the University of

California, Davis, where she performed genetic research forsix years.

Kathy established a career in the financial services indus-try, working with Robertson Stephens & Co. from 1983through 1996, at which time the firm was sold. During thistenure, she became a general partner and managing direc-tor. Dr. Behrens continued in her capacity as a GeneralPartner for selected venture funds for RS Investments from1996 through today, after management led a buy-out ofthat firm from Bank of America. Her professional careerincluded tenures as a public-market biotechnology securi-ties analyst, as well as venture capitalist focusing onhealthcare, technology and related investments. She wasinstrumental in the founding of several biotechnology com-panies including Protein Design Labs, Inc. and CORTherapeutics, Inc. and participated in financing a broadrange of biotechnology, health services and device compa-nies. Most recently, Kathy served as a director of Abgenix,Inc. in a role that spanned that firm’s early rounds of pri-vate financings through the company’s sale in 2006 toAmgen, Inc.

Richard M.J. Bohmer, MB, ChB, MPH Richard M.J. Bohmer is a physician and the MBA Class of1973 Senior Lecturer in Business Administration at theHarvard Business School in the Technology and Operations(TOM) unit. He teaches a second year course on health careoperations management, "Managing Medicine," which dis-cusses the design, management and improvement of the

processes by which patients are med-ically treated. He co-directs the MD-MBAprogram and teaches a course atHarvard Medical School on medicalmanagement. He is the faculty chair forthe Executive Education programHealthcare Delivery.

His research has focused on healthcare operations strategy, technologyadoption in health care, patient safety,

clinical process management and clinical quality improve-ment. Central to his teaching and research is the principlethat health care delivery requires different types of process,each of which must be managed in a different way.Professor Bohmer has written on learning, technologyadoption and health care operations strategy in the medicaland management literatures and published numerous caseson health care operations management. In 2004 he was amember of the Institute of Medicine committee that pro-duced the report “Saving Women’s Lives: Strategies forImproving Breast Cancer Detection and Diagnosis.”

Before joining the HBS faculty, Dr. Bohmer was a SeniorClinical Associate at Massachusetts General Hospital andthe Clinical Director of Quality Improvement for four years,where he was responsible for planning and implementingthe clinical quality improvement program at the hospital.



14

Conference Speakers continued

Dr. Bohmer was born in Wellington, New Zealand. Hetrained at the Auckland University School of Medicine inFamily Medicine, and has practiced medicine in NewZealand, England and Africa. He attended the HarvardSchool of Public Health on a Fulbright Scholarship fromwhere he graduated in 1993 with a Masters of PublicHealth in Health Care Management. He has taught andconsulted on health management issues in numerous loca-tions both in the US and internationally.

Mary Del BradyMs. Brady, President and CEO of RedPath IntegratedPathology, Inc., is an entrepreneur whose 30 years of pro-fessional experience include the founding and ownership ofseveral companies in the services and biotechnology indus-tries.

She has held an executive role within a major academichealth system, was president of a national association ofbusiness owners with international responsibilities, and hasserved as a director/advisor for numerous not-for-profit andfor-profit organizations.

Prior to joining RedPath, Ms. Brady was co-founder andpresident of the highly regarded TissueInformatics.Inc, oneof Western Pennsylvania's earliest first biotechnology com-panies. She holds a Masters in Business Administrationfrom the University of Pittsburgh.

David J. Brailer, M.D., Ph.D.David J. Brailer, MD, PhD, chairman of Health EvolutionPartners, has sought to drive positive change in health carein his work as a physician, researcher, teacher, entrepreneur

and policymaker. He earned his MD atWest Virginia University, completedinternal medicine residency at theUniversity of Pennsylvania School ofMedicine, and earned his PhD in healtheconomics at The Wharton School. Dr.Brailer taught in Wharton’s MBA curricu-lum for ten years.

Dr. Brailer founded CareScience, Inc.and served as Chairman and CEO from

inception, through its IPO and until its sale in 2002.CareScience led the market in development of care man-agement, outcomes analysis and health informationexchange under his leadership.

President George W. Bush appointed Dr. Brailer as thefirst National Coordinator for Health InformationTechnology, and he served in this role from May 2004through May 2006. Dr. Brailer oversaw the President'sExecutive Order, which called for widespread deployment ofhealth information technology within ten years to help real-ize substantial improvements in safety and efficiency.

David D. Chang, M.D., Ph.D.Since joining Amgen in 2002, David Chang has played aninstrumental role in defining Amgen’s strategy in entry ofsmall molecule and biologic therapeutics into clinical test-

ing. He has managed several programsin anti-angiogenesis, cell proliferation,and apoptosis, and was the lead clinicalscientist in biomarker development pro-gram in oncology. He was also a keyclinical strategist for several late stageprograms. In 2005, he assumed leader-ship of the Oncology Therapeutics pro-gram and currently oversees clinicaldevelopment of oncology therapeutics

portfolio at Amgen.Dr. Chang received his B.S. from Massachusetts Institute

of Technology, his M.D. and Ph.D. from Stanford UniversitySchool of Medicine in 1988, and his postgraduate clinicaltraining at the Brigham and Women's Hospital and theDana Farber Cancer Institute. Prior to joining Amgen, Dr.Chang served on the faculty at the School of Medicine,UCLA. He is a recipient of the Searle Scholars Award,James McDonnell Scholars Award, and the PresidentialEarly Career Award for Scientists and Engineers.

Clayton M. Christensen, D.B.A.Clayton M. Christensen is the Robert and Jane CizikProfessor of Business Administration at the HarvardBusiness School, with a joint appointment in the Technology& Operations Management and General Management fac-

ulty groups. His research and teachinginterests center on the managementissues related to the development andcommercialization of technological andbusiness model innovation. Specificareas of focus include developing orga-nizational capabilities and finding newmarkets for new technologies.

Professor Christensen holds a B.A.with highest honors in economics from

Brigham Young University (1975), and an M.Phil. in appliedeconometrics and the economics of less-developed coun-tries from Oxford University (1977), where he studied as aRhodes Scholar. He received an MBA with High Distinctionfrom the Harvard Business School in 1979, graduating as aGeorge F. Baker Scholar. He was awarded his DBA from theHarvard Business School in 1992. Prior to joining the HBSfaculty, Professor Christensen served as chairman and presi-dent of Ceramics Process Systems Corporation (CPS), a firmhe co-founded with several MIT professors in 1984. CPS is aleading developer of products and manufacturing processesusing high-technology metals and ceramics such as siliconnitride and silicon carbide. From 1979 to 1984 he workedas a consultant and project manager with the BostonConsulting Group (BCG), where he was instrumental in

15

founding the firm's manufacturing strategy consulting prac-tice. In 1982 Professor Christensen was named a WhiteHouse Fellow, and served through 1983 (on a leave ofabsence from BCG) as assistant to U.S. TransportationSecretaries Drew Lewis and Elizabeth Dole.

Professor Christensen became a faculty member at theHarvard Business School in 1992. He taught courses inTechnology and Operations Management, GeneralManagement, and Operations Strategy. He then developeda course called Managing Innovation. Professor Christensencurrently teaches an elective course he designed calledBuilding a Sustainably Successful Enterprise, which teachesmanagers how to build and manage an enduring, success-ful company or transform an existing organization.

Professor Christensen is the author of the bestsellingbooks The Innovator’s Dilemma (1997), which received theGlobal Business Book Award for the best business bookpublished in 1997, The Innovator's Solution (2003), andSeeing What's Next (2004). In addition, he edited two case-books on Innovation: Innovation and the General Manager(1999) and Strategic Management of Technology andInnovation, 4th edition (2004).

Professor Christensen's writings have been featured in avariety of publications, and have won a number of awards,such as the Best Dissertation Award from The Institute ofManagement Sciences for his doctoral thesis on technologydevelopment in the disk drive industry; the Production andOperations Management Society's 1991 William AbernathyAward, presented to the author of the best paper in themanagement of technology; the Newcomen Society’s awardfor the best paper in business history in 1993; and the 1995and 2001 McKinsey Awards for articles published in theHarvard Business Review.

Professor Christensen was born in Salt Lake City, Utah.He worked as a missionary for the Church of Jesus Christ ofLatter-Day Saints in the Republic of Korea from 1971 to1973 and speaks fluent Korean. He continues to serve in hischurch in a variety of ways and is extensively involved inother activities in the community. He served from 1986 to1994 as a member of the Program Review Board andStrategic Planning Committee of the Brigham and Women'sHospital in Boston, and was a member and chairman of theboard of directors of the Massachusetts Affiliate of theAmerican Diabetes Association between 1984 and 1996.Professor Christensen was also a founding board memberof the Combined Health Appeal of NortheasternMassachusetts. He was an elected member of the TownMeeting (council) in Belmont Massachusetts for eight years;served as vice-chairman of the town's personnel board; andas chairman of its long-range financial planning task force.He has served the Boy Scouts of America for 25 years as ascoutmaster, cubmaster, den leader and troop and packcommittee chairman. He and his wife Christine live inBelmont, MA. They are the parents of five children.

George Church, Ph.D.Professor of Genetics, Harvard Medical School, Director ofthe Center for Computational Genetics. 1984 Harvard PhD

included the first direct genomicsequencing method, molecular multi-plexing tags, which lead to automation& software used at Genome TherapeuticsCorp. for the first commercial genomesequence -- pathogen, Helicobacter in1994. This multiplex solid-phasesequencing evolved into polonies (1999),ABI-SOLiD (2005) & open-sourcePolonator.org (2007). Innovations in

homologous recombination and array-based DNA reading &writing lead to current research and new ethics/safetystrategies in Personal Genomics (PGP, 23andme, Knome) &synthetic biology (Codon Devices, SynBERC, LS9).

Nadine Cohen, Ph.D.Nadine Cohen was trained as a pharmacist in France andreceived her Ph.D. in Immunogenetics in 1986 from theHebrew University in Jerusalem. She was a post-doctoratefellow at Stanford University until 1989, and after heading

the genetic screening laboratory at theFoundation Jean Dausset-HumanPolymorphism Study Center in Paris, shewas an Assistant Professor from 1995-2001 at the Technion Bruce RappaportFaculty of Medicine in Haifa (Israel). Shejoined the Jansen Research Foundationin August 1999 to establish aPharmacogenomics program. She is cur-rently Head of the Pharmacogenomics

Team at the Johnson and Johnson Pharmaceutical Researchand Development (Raritan, NJ, USA). She has publishedmore than 70 scientific papers in the area of immunogenet-ics and human molecular genetics. Nadine Cohen is alsothe current elected chair of the industry PharmacogeneticsWorking Group, and represents Johnson and Johnson onvarious external organizations engaged inPharmacogenomics and Personalized Medicine. NadineCohen is also the invited editor of the book“Pharmacogenomics and Personalized Medicine”, to bepublished in August 2008 by Springer-Human Press.

Jorge CondeCo-Founder and CEO Jorge Conde is President and CEO ofKnome, Inc. He has spent his entire professional career inthe biotechnology industry, working in finance, businessdevelopment, marketing and operations. Prior to Knome,Mr. Conde worked in strategic marketing and operations atMedImmune, Inc. He has also worked in business develop-ment at Helicos Biosciences Corporation, a DNA sequencingcompany, and in the life sciences group at FlagshipVentures, a venture capital firm. Previously, Mr. Conde was

continued



16


an investment banker at Morgan Stanley & Co., specializingin the biotechnology and genomics industries. He holds anMBA from Harvard Business School, an MS from theHarvard-MIT Division of Health Sciences and Technology(HST) and a Bachelor's degree in Biology from The JohnsHopkins University.

Mark A. Creager, M.D.Mark A. Creager is Professor of Medicine at HarvardMedical School, a member of the Cardiovascular Division,and Director of the Vascular Center at the Brigham andWomen’s Hospital in Boston. Dr. Creager earned his med-ical degree at Temple University in Philadelphia, followingwhich he was Clinical and Research Fellow in PeripheralVascular Disease and subsequently Cardiology Fellow at

University Hospital and Boston CityHospital. He has been the recipient ofmany awards and honors, and is cur-rently the Simon C. Fireman Scholar inCardiovascular Medicine at Brigham andWomen’s Hospital.

Dr. Creager’s major research and clini-cal interest is in vascular medicine,specifically vascular regulatory mecha-nisms. He is an editor of the textbook,

Vascular Medicine and the editor of the journals, VascularMedicine and Current Treatment Options in CardiovascularMedicine, and a member of the editorial boardArteriosclerosis, Thrombosis and Vascular Biology. He is theauthor of more than 280 published contributions to themedical literature, including: research papers on vascularfunction, book chapters, and monographs on vascular dis-ease. He is a member of the Board of Directors of theAmerican Heart Association, and the American Board ofVascular Medicine. Dr. Creager currently serves as Presidentof the Vascular Disease Foundation. He is Past Presidentand Master of the Society for Vascular Medicine, and aFellow of the American Heart Association, the AmericanCollege of Cardiology, and the American PhysiologicalSociety.

Arthur A. Daemmrich, Ph.D.Arthur Daemmrich is an assistant professor in the Business,Government, and the International Economy Unit and a

member of the interdisciplinary HBSHealthcare Initiative. His work examinesthe regulation of science-based indus-tries, with a particular emphasis on com-parative risk analysis and the interplayof changing scientific knowledge withbusiness practices in the pharmaceuticaland chemical sectors.

Dr. Daemmrich has published on phar-maceutical regulation, biotechnology

policy and politics, and innovation in industrial chemistry.His 2004 book, Pharmacopolitics, compares drug regulation

in the United States and Germany, with a focus on regula-tory laws, clinical trials, and adverse reaction reporting sys-tems in the two countries. His edited volume, Perspectiveson Risk and Regulation: The FDA at 100 (2007) broughttogether the viewpoints of FDA officials and industry lead-ers on the future of regulating pharmaceuticals, medicaldevices, food, and dietary supplements. Dr. Daemmrich iscurrently advancing a comparative study of chemicals regu-lation in the United States and European Union. He is alsoinitiating a research project on healthcare and informationtechnology, which will compare internationally the legaland regulatory boundaries countries put on the ability tocommercialize health information and what this tells usabout the prospects for global healthcare businesses.

Dr. Daemmrich holds a Ph.D. in Science and TechnologyStudies from Cornell University and a B.A. in History andSociology of Science and German Literature (dual-degree)from the University of Pennsylvania. He was a Fellow at theKennedy School of Government at Harvard University in1999-2000. Before coming to HBS, Daemmrich was thefounding director of the Center for Contemporary Historyand Policy at the Chemical Heritage Foundation inPhiladelphia. Under Daemmrich's leadership, the Centergrew rapidly to encompass programs on innovation andentrepreneurship, risk and regulation, and scientific andindustrial infrastructure.

Neil de CrescenzoOracle Corp. has created a Health Sciences Global BusinessUnit and named Neil de Crescenzo to lead it as senior vicepresident and general manager.

Neil de Crescenzo most recently served as group vicepresident of healthcare and life sciences at Oracle. He previ-ously led Perot Systems Corp.’s health care provider strate-gy unit and was healthcare industry leader at IBM Corp. Healso has served in administrative positions atMassachusetts Medical Center, Lahey Clinic and Blue CrossBlue Shield of Massachusetts.

Mr. de Crescenzo received his BA in Political Science fromYale University.

Janet Dillione As CEO of the Healthcare IT Division for Siemens MedicalSolutions, Janet Dillione is passionate about having a posi-tive impact on patient care through the use of technology.With her in-depth knowledge of the healthcare environ-ment and her long-standing partnerships with customers,Dillione understands that information technology (IT) is agreat enabler, giving nurses and physicians more time tospend delivering quality patient care.

In her current position, Dillione leads Siemens globalhealthcare IT business, including strategy and portfoliomanagement, profit and performance, and customer satis-faction. With her broad range of expertise in product devel-opment and marketing, country-specific operations, saleschannel management, and customer relationship manage-

17

ment, she brings her unique drive to represent the voice ofthe customer in every action and every decision, with theultimate goal of having a positive impact on the future ofhealthcare.

Dillione has 25 years of experience in the healthcareinformation services industry. With Siemens since 2000,Dillione most recently served as chief operating officer(COO) for the Healthcare IT Division, and also served assenior vice president of U.S. Healthcare IT BusinessManagement, with operating responsibility for profitability,market share growth and customer satisfaction throughoutthe country. Her prior role was serving as group vice presi-dent, global financial systems. Dillione’s astute manage-

ment and domain knowledge of infor-mation systems were key in leading thedevelopment and launch of Siemensnext generation Soarian® solution, apremier workflow-based HIT solution.

Prior to Siemens, Dillione spent 18years at Shared Medical Systems (SMS),starting as a systems consultant andmoving into positions of increasedresponsibilities on a regular basis. Her

years at SMS gave Dillione a well-rounded view of thehealthcare information systems landscape since she workedin both the financial and clinical solutions arenas,as well as in technical and management positions.

A member of the Health Information and ManagementSystems Society (HIMSS) Advisory Board (2005-2007 term)and a frequent speaker at industry forums, Siemens user-group meetings and conferences, Dillione passionately sup-ports efforts to improve the quality and safety of healthcaredelivery and technology’s role in doing so.

In April 2007, Dillione was named as one of the “Top 25Women in Healthcare” by Modern Healthcare magazine.She shares this prestigious honor with other US leaderssuch as Senator Hilary Rodham Clinton; Julie Gerberding,Director, Center for Disease Control (CDC); and AngelaBraly, recently appointed president of WellPoint, the US’largest private health insurer. In compiling the listing,Modern Healthcare editors cited the growing number ofinfluential women who are leading healthcare systems, cor-porations, government agencies, philanthropic organiza-tions, and professional associations. Worth noting is thatDillione is the only representative of the healthcare infor-mation systems industry on the list. Dillione also secured acoveted spot on VARBusiness magazine’s August 2007 “50Most Powerful Women of the Channel” listing. Additionally,HIMSS recognized Dillione’s contributions to the industry byawarding her with a 2007 Board of Directors ServiceAward.

Dillione has a Bachelor of Arts degree in bio-medicalethics from Brown University and is a graduate of theWharton School’s Executive Management Program. Shelives in West Chester, Pa., with her husband and twodaughters.

Gregory J. Downing, D.O., Ph.D.Dr. Downing is Director of the Office of Technology andIndustrial Relations (OTIR) in the Office of the Director atthe National Cancer Institute (NCI), National Institutes ofHealth. In this role, he facilitates the collaboration amongFederal, academic, and private biomedical research sectorsto support technology development that will yield innova-tive diagnostic, detection, and targeted treatment strategiesfor cancer. Through the OTIR, he supervises the administra-tion of grants and contracts for programs in nanotechnolo-gy, biosensors, therapeutic delivery systems, and new tech-nology platforms and imaging systems. He currently serveson several committees, including the NCI-FDA InteragencyOncology Task Force and the Biomedical InformationScience and Technology Consortium.

Dr. Downing began his career at the NIH in 1994 as a fel-low at the National Institute for Child Health and HumanDevelopment, and subsequently served in the Office ofScience Policy and Planning as a health science policy ana-lyst and deputy director. Today, he continues to lead theimplementation of training and programs that support theresearch policy goals of the NIH.

Dr. Downing earned his medical degree from MichiganState University and his Ph.D. in pharmacology from theUniversity of Kansas. He completed his residency in pedi-atrics and fellowship in neonatology before joining the fac-ulty of the University of Missouri-Kansas City in theDepartment of Neonatology at The Children’s MercyHospital.

Dr. Downing is certified by the American Board ofPediatrics in pediatrics and neonatology— perinatal medi-cine. He sits on the editorial board of the Journal ofMaternal-Fetal Investigation and is Associate Editor ofDisease Biomarkers. He has published numerous articlesand research in the fields of pharmacology and medicineand has contributed to three books.

Deborah Dunsire, M.D.Dr. Dunsire joined Millennium in July, 2005 with nearly 20years of experience in commercial, operational, clinical andscientific aspects of a world-leading pharmaceutical busi-ness. Her vision for Millennium was to establish a vibrant,growing biotechnology company, which discovers anddevelops new medicines that change standards of care incancer and inflammation.

In April of 2008, Millennium was acquired by TakedaPharmaceuticals of Japan to become the centerpiece forachieving their global vision of Oncology Leadership by2020. Dr Dunsire remains as President and CEO ofMillennium, the Takeda Oncology Company. The current latestage immunology compounds will continue to be devel-oped at Millennium but commercialized through Takeda.

Previously, Dr. Dunsire led the Novartis U.S. Oncologybusiness and played a critical role in the broad develop-ment and launch of successful products such as Zometa®,Femara® and Gleevec®. Notably, Dr. Dunsire managed 12

continued



18


product launches and built the business from approximately $50 million to $2.1 billion in revenues over 10 years.

Earlier in her career, she was a clinical researcher respon-sible for the implementation of global Phase II and Phase IIIstudies across multiple therapeutic areas, including

immunology, endocrinology, neurology,dermatology, oncology and transplanta-tion.

Dr. Dunsire graduated from medicalschool at the University ofWitwatersrand in Johannesburg, SouthAfrica. In 2006, she was also awarded aDoctor of Science, Honoris Causa, fromWorcester Polytechnic Institute.Currently, Dr. Dunsire is a board member

of Biotechnology Industry Organization (BIO), Allergan, Inc.,the Museum of Science (Boston), CancerCare (New York)and the G&P Foundation for Cancer Research. She is also amember of the Massachusetts Women’s forum and theHealthcare Business Women’s Association.

Dr. Dunsire was the 2001 recipient of the AmericanCancer Society Excalibur award, the 2000 recipient of theHealth Care Business Women's Association Rising Staraward and also the Creative Spirit award from the CreativeCenter for Women with Cancer.

Robert S. Epstein, M.D., M.S.Dr. Robert S. Epstein joined Medco in 1995 and has servedas Medco’s Senior Vice President of Medical & AnalyticalAffairs and Chief Medical Officer since 1997. In this capaci-ty, he is responsible for formulary development, clinical

guidelines, drug information services,accreditation oversight, and personal-ized medicine services. He is alsoresponsible for analysis and reportingfor Medco’s clients. Dr. Epstein wastrained as an epidemiologist, andworked in public health and academiabefore joining the private sector. He ispast elected President of theInternational Society of

Pharmacoeconomics and Outcomes Research, and hasserved on the Board of Directors for the Drug InformationAssociation. He has published more than 50 peer reviewedmedical articles and book chapters, and serves as a review-er for several influential medical journals.

Mason Freeman, M.D.Mason Freeman, MD is Chief of the Lipid Metabolism Unitat Massachusetts General Hospital, Harvard MedicalSchool. Trained in internal medicine and endocrinology, Dr.Freeman has spent the past twenty years studying the traf-ficking of cholesterol into and out of macrophages. Hefounded and still directs the Lipid Clinic at MGH and is aninternationally recognized expert in the treatment of lipid

disorders. In 2005, Dr. Freeman took a sabbatical fromHarvard to work as Vice-President and Global Head ofTranslational Medicine for Cardiovascular, Diabetes, and

Metabolic Diseases at the NovartisInstitutes of Biomedical Research inCambridge, MA. In this role, he and histranslational medicine team wereresponsible for designing the earlydevelopment programs for drugs affect-ing hypertension, diabetes, obesity, ath-erosclerosis and lipid disorders. Onreturning to MGH in 2007, he assumedthe dual roles of Director of the

Genetics Enters Medicine trials in Partners and Director ofTranslational Medicine at MGH. Dr. Freeman received hisA.B from Harvard College, M.D. from the University ofCalifornia, San Francisco, and did post-doctoral training incell biology and lipid metabolism at MIT.

Felix W. Frueh, Ph.D.Dr. Felix Frueh joined Medco in May 2008 to head up anewly created R&D organization for Personalized Medicineand expand Medco's leadership in this field. In this func-tion, Dr. Frueh is responsible for the strategy and oversightof new research initiatives that will help to better assess

the safety and effectiveness of drugtherapies at the level of individualpatients. Dr. Frueh joined Medco afterfour years as Associate Director forGenomics at the U.S. FDA, where hebuilt and led a core genomics reviewteam in the Center for Drug Evaluationand Research (CDER), and chaired thefirst FDA-wide, interdisciplinary pharma-cogenomics review group (IPRG). Prior

to the FDA, he was Managing Partner at StepoutsideConsulting, LLC, and held senior positions at Transgenomicand Protogene Laboratories. His academic career includesa faculty appointment at the Departments of Pharmacologyand Medicine at Georgetown University in Washington DC,and postdoctoral fellowships at Stanford University and theUniversity of Basel, Switzerland, where he also received hisPh.D. in biochemistry. Dr. Frueh is a native of Switzerlandand lives in Maryland with his wife and two sons.

John Glaser, Ph.D.John Glaser, PhD, is Vice-President and Chief InformationOfficer, Partners HealthCare System, Inc. Previously, he wasVice-President, Information Systems at Brigham andWomen’s Hospital. Prior to Brigham and Women's Hospital,Dr. Glaser managed the Healthcare Information Systemsconsulting practice at Arthur D. Little.

Dr. Glaser was the founding Chairman of College ofHealthcare Information Management Executives (CHIME)and is past President of the Healthcare Information and

19

Management Systems Society (HIMSS). He has been amember of the Board of the American Medical InformaticsAssociation.

Dr. Glaser is currently the Chairman of the eHealthInitiative Board and the Senior Advisor for National HITAdoption for CHIME. He is a Senior Advisor to the Deloitte

Center for Health Solutions.He is a fellow of HIMSS, CHIME and

the American College of MedicalInformatics. He has been awarded theJohn Gall award for healthcare CIO ofthe year. CHIME has established a schol-arship in Dr. Glaser’s name. He was arecipient of CIO Magazine’s 20/20 VisionAward. Partners HealthCare has receivedseveral industry awards for its effective

and innovative use of information technology.Dr. Glaser has published over one hundred articles and

four books on the strategic application of information tech-nology in healthcare.

He holds a Ph.D. in Healthcare Information Systems fromthe University of Minnesota.

Harry GlorikianHarry Glorikian is recognized worldwide as a leader in help-ing companies accelerate the development of their busi-nesses with a combination of robust analysis and deepcommercial/technical experience. Harry’s expertise spansmore than two decades within the life sciences/healthcareindustry. His unique understanding of both buyer and inter-nal company perspectives has shaped the methodology andframework analysis tools Scientia uses to create sophisti-cated, enduring business strategies that capture and sus-tain optimal value.

Harry is regularly quoted in industry magazines and peri-odicals and writes articles about life sciences/healthcare

and business strategies regularly. He is afrequent speaker at industry events andoften is asked to provide insight to themedia and industry leaders on life sci-ences/healthcare and current businesstrends.

In Harry’s past experience he has heldseveral senior management positionswith many leading life science firms.Harry’s experience spans many different

areas: Diagnostics, Molecular Biology, Proteomics andCellular Biology as well as in the area of Biodefense.

Currently Harry serves on the advisory board of DraperLaboratories. He is an avid inventor with 2 issued USpatents and more pending both in the US and internation-ally.

Harry holds a Bachelor of Business Administration degreeand a Master of Business Administration degree fromBoston University.

Alexandra Glucksmann, Ph.D.Alexandra Glucksmann is currently Senior Vice President ofResearch and Business Operations at TempoPharmaceuticals, which she joined in October 2006 at itsfounding. Tempo Pharmaceuticals is developing a propri-etary nanoparticle technology designed to improve thesafety and efficacy of marketed and development-stagedrugs. Prior to joining Tempo, she spent 13 years atMillennium Pharmaceuticals which she joined in 1993 asone of its first scientists. At Millennium, she held a series ofpositions with increasing responsibility, ultimately becomingvice president of all platform technology groups beforemoving into a senior role in strategic program managementand operations, where she worked closely with the CEOand led company-wide process improvement initiatives andparticipated in business development and M&A efforts.During her tenure at Millennium, Alexandra was critical tohelping Millennium evolve from a genomics research-focused organization to a fully integrated pharmaceuticalscompany with products on the market. Her division playedan integral role in the numerous Millennium-large pharmacollaborations, which generated over $1.8 billion in fundingfor the company.

She serves on the Board of Directors of Taconic Farmsand is a Chair of the Board of Women Entrepreneurs inScience and Technology. She is also a member of GeneticsAdvisory Council of the Harvard-Partners Center forGenetics and Genomics.

Alexandra was a post-doctoral fellow at theMassachusetts Institute of Technology and holds a Ph.D.with honors from the University of Chicago.

Matthew P. Goetz, M.D.I am a breast cancer oncologist with a research focus in thedevelopment and validation of biomarkers for breast can-cer. My work is performed in collaboration with the labora-tory of Matthew Ames, Ph.D., who chairs the Department ofMolecular Pharmacology and Experimental Therapeutics atMayo Clinic. My additional key collaborators at Mayo Clinicare James Ingle, M.D., (PI, Mayo Breast SPORE), RichardWeinshilboum, M.D., (PI, Mayo PGRN), and ThomasSpelsberg, Ph.D.

A notable area of our focus is the pharmacogenetics oftamoxifen biotransformation, and our work with CYP2D6has led to a recent FDA recommendation to change thelabel of tamoxifen to incorporate the importance of geneticand drug-induced variation in CYP2D6. I am principle inves-tigator of ongoing studies (1R01 CA133049-01) focused onthe pharmacogenetics of tamoxifen biotransformation incollaboration with the laboratories of Dr. Matthew Amesand Dr. Richard Weinshilboum. These studies are designedto understand the role of CYP2D6 as a tool to individualizehormonal therapy in the adjuvant setting, and to under-stand the effect of commonly administered drugs on theactivity of CYP2D6 in tamoxifen treated women. This latteractivity is being performed in collaboration with the

continued



20


Consortium of Breast Cancer Pharmacogenomics (COBRA).Additionally, we are studying the role of the 13C - DMbreath test as a marker of CYP2D6 activity in tamoxifentreated patients in collaboration with Physical Sciences, Inc.and Cambridge Isotope Laboratories, Inc.

In addition to NCI funding, I am a funded investigator inthe Mayo Pharmacogenetics Research Network grant(Richard Weinshilboum, PI), and a past recipient of a CareerDevelopment Award (Mayo Breast Cancer SPORE), and PaulCalabresi Scholar Award (K-12).

My interest in pharmacogenetics also extends to irinote-can, and our group has been the first to demonstrate thatUGT1A1*28 genotype affects the maximally tolerated doseof irinotecan-based therapy. We have several ongoing NCI-sponsored trials in which the recommended phase II doseof therapy will be dependent upon UGT1A1 genotype.

Finally, I am a member of the Phase I group at MayoClinic, and I am working with the Ames laboratory in bothpre-clinical and clinical development of drugs focused onbreast cancer including the drug aminoflavone.

Richard G. Hamermesh, D.B.A.Richard Hamermesh is the MBA Class of 1961 Professor ofManagement Practice at the Harvard Business Schoolwhere he teaches in the MBA Program and is the FacultyChair of the HBS Healthcare Initiative. Richard created andteaches the second-year MBA elective, Entrepreneurshipand Venture Capital in Healthcare. Previously, he was theCourse Head for the required first year course entitled TheEntrepreneurial Manager.

From 1987 to 2001, Richard was a co-founder and aManaging Partner of The Center for Executive Development,an executive education and development consulting firm.Prior to this, from 1976 to 1987, he was a member of thefaculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, hav-ing participated as a principal, director, and investor in the

founding and early stages of over 20organizations. These have included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He wasthe founding president of the Newton(MA) Schools Foundation and served onthe editorial board of the HarvardBusiness Review. He is currently on theBoards of one public and two privatecorporations, as well as two non-profit

Boards. From 1991 to 1996, he was the founding Chairmanof Synthes Spine, Inc. Richard is the author or co-author offive books, including New Business Ventures and theEntrepreneur. His best-known book, Fad-Free Management,was published in 1996. He has published numerous articlesand more than 100 case studies. Richard received his ABfrom the University of California, and his MBA and DBAfrom HBS. He is married, has two children, and his hobbiesinclude tennis, skiing, and yoga.

James Allen HeywoodJamie is the co-founder and chairman of PatientsLikeMewhere patients share in depth information on treatments,symptoms, and managing disease. PatientsLikeMe is a per-sonalized research platform for patients, pharmaceuticaland biotech companies as well as non-profits to better

understand disease, improve care andaccelerate the development of newtreatments and biomarkers.

Jamie is the d’Arbeloff founding direc-tor of ALS Therapy DevelopmentInstitute, the world’s first non-profitbiotechnology company and served asits CEO from 1999 to 2007. Pioneeringan open research model and an industri-

alized therapeutic validation process under Jamie’s leader-ship ALS TDI grew to being the worlds largest ALS researchprogram.

An MIT engineer, he entered the field of translationalresearch when his brother Stephen was diagnosed with ALSin 1998 at the age of 29. His work has been profiled in theNew Yorker, 60 Minutes, Pulitzer Prize winner JonathanWiener’s book, His Brothers Keeper, and in the Sundanceaward winning documentary So Much So Fast.

Diane KeoghDiane Keogh is the Corporate Director for ResearchComputing, Partners HealthCare Systems, Inc. This positionprovides enterprise IT strategy and systems support for thebiomedical research community at Massachusetts GeneralHospital, Brigham and Women’s Hospital and affiliated hos-

pitals. This includes administrative sys-tems, site infrastructure teams, enter-prise infrastructure, genetics andgenomics IT, and enterprise researchrepositories.

Previously she held the position ofCorporate Director of Enterprise Servicesat Partners HealthCare focusing on clini-cal integration, non-acute, and research

IT. She also spent 10 years as Chief Information Officer atNewton-Wellesley Hospital.

Ms. Keogh has over 25 year experience in healthcare ITcovering industry, community hospitals, academic hospitals,and biomedical research with a major focus on developingscalable enterprise strategies and solutions.

David P. KingDavid P. King has served as President and Chief ExecutiveOfficer and a director of the Company since January 1,2007. Prior to that date, Mr. King served as Executive VicePresident and Chief Operating Officer from December 2005to January 2007, as Executive Vice President of StrategicPlanning and Corporate Development from January 2004 toDecember 2005 and was hired in September 2001 as SeniorVice President, General Counsel and Chief Compliance

21

Officer. Mr. King is a member of the Executive Committee ofthe Company. Prior to joining the Company, he was a part-ner with Hogan & Hartson L.L.P. in Baltimore, Marylandfrom 1992 to 2001.

Raju Kucherlapati, Ph.D.Raju Kucherlapati came to the United States in 1967 afterreceiving his B.S. in Biology at P.R. College, Kakinada, Indiaand his M.S. in Biology at Andhra University, Waltair, India.He received his Ph.D. from the University of Illinois atUrbana and did his post-doctoral work in the lab of FrankRuddle at Yale University. He was assistant professor in theDepartment of Biochemical Sciences at Princeton University,then became professor in the Department of Genetics atthe University of Illinois College of Medicine. In 1989 Dr.Kucherlapati went to the Albert Einstein College ofMedicine where he was the Lola and Saul Kramer Professorof Molecular Genetics and Chairman of the Department ofMolecular Genetics, a position he held for eleven years. In2001 Dr. Kucherlapati became the Paul C. Cabot Professor

of Genetics and Professor of Medicine atHarvard Medical School and was thefirst Scientific Director of the HarvardMedical School-Partners HealthCareCenter for Genetics and Genomics(HPCGG).

At HPCGG Dr. Kucherlapati is devotinghis energies to advancing the cause ofpersonalized medicine. Under his direc-tion HPCGG launched initiatives that

resulted in a large number of novel molecular diagnostics;built new information technology programs that capturedthe results of clinical and basic genetic research in struc-tured formats that could then be applied meaningfully inclinical decision making that would benefit diagnosis, prog-nosis and treatment of patients. He also strengthened anddeveloped new training and educational programs forphysicians, scientists, healthcare professionals, patients, andothers in human genetics and genomics and the applicationof genetics in healthcare.

Dr. Kucherlapati contributed to several different areas ofresearch. These include human gene mapping, generationof physical maps of the human genome with specialemphasis on human chromosome 12, development of tech-niques to modify genes in mammalian cells and in cloningmany human disease genes. To date he holds 12 patents.He was a member of the National Advisory Council forHuman Genome Research at the National Human GenomicsResearch Institute, was a co-chair of the steering committeefor the National Cancer Institute’s Mouse Models forHuman Cancer Consortium. He served on the editorialboard of the New England Journal of Medicine and waseditor in chief of the journal Genomics. He is a fellow ofthe American Association for the Advancement of Scienceand a member of the Institute of Medicine.

Dr. Kucherlapati was a founder of Cell Genesys, Abgenixand Millennium Pharmaceuticals. He currently serves onthe boards of privately held AVEO Pharmaceuticals andEnlight Biosciences.

Michael O. Leavitt U.S. Department of Health and Human ServicesMichael O. Leavitt was sworn in as the 20th Secretary ofthe U.S. Department of Health and Human Services onJanuary 26, 2005. As Secretary, he leads the Nation’s efforts

in protecting the health of all Americansand providing essential human servicesto those in need.Following his core principles, SecretaryMike Leavitt uses a 500-Day Plan as amanagement tool to guide his energiesin fulfilling the President’s vision of ahealthier and more hopeful America. Theplan is both flexible and dynamic. The250-Day Update reflects the evolution of

the Secretary’s original 500-Day Plan. Based on theseguides, Secretary Leavitt has identified his priorities for thecoming year.

Frederick S. Lee M.D., MPH In his role as Product Manager for McKesson, Fred isresponsible for strategies that enhance the clinical electron-ic health record to support personalized medicine andleverage advanced molecular diagnosis. He is also responsi-ble for evaluating trends and opportunities in the broadermolecular and in vitro diagnostics industries.

Fred has over 10 years of experience in healthcare infor-mation technology and executive leadership. Prior to hiscurrent role with McKesson, Fred led product strategy forelectronic healthcare record systems with GE Healthcare inthe UK market. Fred has also served as Physician Executivefor Dearborn Advisors, a boutique healthcare IT consultancy.He has also served in executive leadership roles as CMIOand COO for a large ambulatory care network in New YorkState.

Fred’s clinical background is in General Surgery andPreventive Medicine, having received his MD degree andclinical residency training from Stony Brook UniversityMedical Center and the Mailman School of Public Health atColumbia University. Fred attended MIT as an undergradu-ate, where he received a Bachelor of Science degree in LifeSciences. He is currently based in Seattle, WA.

Lawrence J. Lesko, Ph.D., FCPLawrence J. Lesko, Ph.D., FCP has been the Director of theOffice of Clinical Pharmacology in the Center for DrugEvaluation and Research at the Food and DrugAdministration since 1995. The main focus of Dr. Lesko’sOffice is the translational analysis of dose-response and PK-PD data for the purposes of optimizing dosing and the ben-

continued



22

efit/risk ratio of FDA-approved drugs, the use of PK and bio-markers to assist in dosing adjustments for drug-drug inter-actions, special populations (e.g., renal patients) and otherpatient subsets defined by pharmacogenomics, individual-ization of drug therapy using plasma drug levels, and theapplication of quantitative methods such as disease stateprogression models and simulations to design clinical trials.Outside FDA, Dr. Lesko has served as President of theAmerican College of Clinical Pharmacology (2004-2006).Prior to joining FDA, Dr. Lesko was a faculty member in aca-demia for over 15 years, most recently at the University ofMaryland. He has directed the clinical pharmacology labo-ratory at the University of Massachusetts Medical Center,and was Vice-President of PharmaKinetics Laboratories, a

Baltimore-based contract researchorganization. He has been appointed asan Adjunct Professor at the University ofFlorida and at the University of SouthernCalifornia in the Colleges of Pharmacywhere he lectures and interacts withgraduate students. Dr. Lesko is anAmerican Association of PharmaceuticalScientist (AAPS) Fellow and is BoardCertified in Clinical Pharmacology by the

American Board of Clinical Pharmacology. He received theRawls-Palmer Progress in Medicine Award from theAmerican Society of Clinical Pharmacology andTherapeutics in March 2007, the University of NorthCarolina Institute of Personalized Medicine Clinical ServicesAward in May 2007 and the Nathaniel T. Kwit MemorialDistinguished Service Award from the American College ofClinical Pharmacology in September 2007. He is a memberof the editorial board of several prestigious journals includ-ing the Journal of Clinical Pharmacology. He has over 145publications in peer-reviewed journals and is a frequentinvited speaker nationally and internationally. His hobbiesare motorcycle riding, scuba diving and underwater photog-raphy. He is a Divemaster certified by the ProfessionalAssociation of Diving Instructors.

Carol J. McCall, FSA, MAAACarol is a Fellow of the Society of Actuaries and has 20years of healthcare experience. She is currently Humana’sVP of R&D where she’s pioneered the use of novel tech-niques in prediction and computational health intelligenceto predict health severity, disease progression and con-sumer health behavior. She also leads Humana’s HealthService Research Center, focused on health services

research, the psychology of healthbehavior change, pharmacovigilance,and personalized medicine research.

“It's boring putting ‘insurance’ as myarea of expertise. I'm interested in any-thing remotely related to health andanything that's weird and cool with dataand analytics. This includes everything

from ubiquitous computing, distributed intelligence, person-al sensor technologies, you name it.

I’m also interested in the ‘social life’ of information – theself-organization, co-creation and emergence of meaning insocial systems – particularly in highly recursive topologies,pervasive information ecosystems, and/or asymmetric infor-mation landscapes. This is where ‘prediction meets peopleand can help them in meaningful ways.”

Jeffrey D. MillerAs Vice President, Worldwide Health and Life Sciences(HLS), Jeff Miller is responsible for market strategy, businessplanning, service offerings, and solutions development forthe healthcare provider, health insurer, pharmaceutical/biotech, and life sciences research market segments. Heoversees the marketing and sales activities for this industrysector, driving overall effectiveness and impact on a globalscale. In addition, Miller has responsibility for strategicoversight of HP’s global sales and services efforts in thePublic Sector.

For several years, Miller has focused his activities onenabling the transformation of the HLS industry as it hasevolved from departmental technology solutions into anecosystem with an integrated set of solutions that allowparticipants across the value chain to digitize content, ana-lyze data, and manage their information collaboratively andeffectively, and where the quality of patient care is criticalto sustainable competitive advantage. During his tenure,industry analysts report that HP HLS revenues have grownto more than $5 billion annually.

Miller has more than twenty years experience in strategicplanning, product development, and operational process

improvement in the health care, manu-facturing, public sector, and technologyindustries. Prior to joining HP, he led thedevelopment and delivery of manage-ment consulting services at The AdvisoryBoard Company and Deloitte Consulting.He has worked with a diverse set ofHealth industry organizations on theidentification and development of trans-formational strategies and the imple-

mentation of technology-enabled business processes.Previously, he managed a variety of business strategy, prod-uct planning, and development operations organizations atIBM.

Miller is based in Research Triangle Park, North Carolina.He holds a master’s of Business Administration from theFuqua School of Business at Duke University in Durham,North Carolina, and a bachelor’s in Economics fromNorthwestern University in Chicago.

Thomas (Tom) J. Miller, Jr.Thomas (Tom) J. Miller, Jr. is Chief Executive Officer (CEO)of Siemens Healthcare’s Workflow and Solutions division.Previously, Tom was a member of the Group Board of


23

Siemens Medical Solutions and has an impressive record ofleadership within Siemens and other multi-national compa-nies. He served as President and CEO, of Health Services,Siemens Healthcare Information Technology business, andhas led the magnetic resonance division and the US salesand service organization.

Additionally, he .was president and CEO of Carl Zeiss,Inc., the American subsidiary of the multi-billion dollar opti-cal company and simultaneously the general manager ofthe worldwide medical division of Carl Zeiss, responsible forsurgical microscopes and ophthalmology products. Tom alsoserved as President and CEO of Analogic Corporation, amanufacturer of components and subsystems for the

healthcare and security industry. He co-founded a company, LightLab Imaging,to commercialize a new diagnosticimaging method called optical coher-ence tomography (OCT) enabling theacquisition and display of real-time ultrahigh-resolution cross sectional imageswith light.

This broad range of experience andexpertise in medical physics and infor-

mation technology have served to shape Tom’s passion formedicine and for transforming how we approach the pre-diction, prevention, diagnosis, and treatment of disease.

Tom holds a B.S. in Nuclear Engineering with a minor inEnglish Literature from the University of Massachusetts anda Masters of Science degree from the Harvard MedicalSchool/Massachusetts Institute of Technology (MIT) jointprogram in Medical Physics.

James J. Mongan, M.D.Dr. Mongan is president and chief executive officer ofPartners HealthCare in Boston, an integrated health systemfounded in 1994 by Brigham and Women’s Hospital andMassachusetts General Hospital.

In addition to its two academic medical centers, thePartners system also includes community hospitals, special-ty hospitals, community health centers, a physician net-work, home health and long-term care services, and otherhealth-related entities.

Partners is one of the nation’s leading biomedicalresearch organizations and a principal teaching affiliate ofHarvard Medical School.

A professor of health care policy and a professor of socialmedicine at Harvard Medical School, Dr. Mongan alsoserves on the board of the Commonwealth Fund and chairsits Commission on a High Performance Health System.

Prior to being appointed president and CEO of Partners,Dr. Mongan was president of Massachusetts GeneralHospital, the largest and oldest teaching affiliate of HarvardMedical School. He also served for 15 years as executivedirector of the Truman Medical Center in Kansas City, alarge public hospital, where he also served as dean of theUniversity of Missouri-Kansas City School of Medicine.

Dr. Mongan spent 11 years in Washington as staff to theSenate Finance Committee, working on Medicare andMedicaid legislation. He later served in the Carter adminis-tration as deputy assistant secretary for health and then at

the White House as associate director ofthe domestic policy staff.

Dr. Mongan is a member of theInstitute of Medicine of the NationalAcademy of Sciences. He has served onthe boards of the American HospitalAssociation and the Kaiser FamilyFoundation, and was a member of boththe Prospective Payment AssessmentCommission established by Congress

and the Institute of Medicine’s Commission on theConsequences of Uninsurance.

A native of San Francisco, Dr. Mongan received his under-graduate education at the University of California, Berkeley,and Stanford University, and his medical degree fromStanford University Medical School. He completed hisinternship at the Kaiser Foundation Hospital in SanFrancisco and served for two years in the U.S. Public HealthService.

Samuel R. Nussbaum, M.D.Dr. Samuel Nussbaum is executive vice president, clinicalhealth policy and chief medical officer for WellPoint, Inc. Heoversees corporate medical policy, clinical pharmacy pro-grams, health improvement and quality resources, programsin clinical excellence, and health information technology tooptimize care for members. His principal responsibilitiesinclude: serving as chief spokesperson and policy advocateon medical issues, guiding the corporate vision regardingquality of care and its measurements, leading efforts toassess cost of care performance and developing a strategyto foster further collaboration with physicians and hospitalsto strengthen and improve patient care. Dr. Nussbaum also

has responsibility for HealthCore,WellPoint’s clinical outcomes researchsubsidiary.

Dr. Nussbaum has served as presidentof the Disease Management Associationof America, Chairman of the NationalCommittee for Quality Health Care, asChair of America's Health InsurancePlan's (AHIP) Chief Medical OfficerLeadership Council and as a member of

the AHIP Board, and currently serves on the NationalQuality Forum (NQF) Board. He received the 2004Physician Executive Award of Excellence from the AmericanCollege of Physician Executives and Modern Physician mag-azine. Dr. Nussbaum is professor of clinical medicine atWashington University School of Medicine and serves asadjunct professor at the Olin School of Business,Washington University.

Dr. Nussbaum served as executive vice president, Medicalcontinued



24

Affairs and System Integration, of the BJC Health Systemand President of its medical group.

Dr. Nussbaum earned his medical degree from MountSinai School of Medicine. He trained in internal medicine atStanford and Massachusetts General Hospital and inendocrinology and metabolism at Harvard andMassachusetts General Hospital, where he directed theEndocrine Clinical Group. His clinical and basic research hasled to new therapies to treat skeletal disorders and newtechnologies to measure hormones in blood.

Lord Naren PatelLord Naren Patel; Member House of Lords; ChairmanEnquiry on Genomics Medicine;

Born Tanzania, Grad. Medicine Univ. St Andrews;Professor Obstetrics and Gynaecology. Chancellor Univ. ofDundee; Fellow Acad. of Med Science; Fellow and VicePresident Royal Society, Edinburgh. M.D. D.Sc. Hon CausaUniv. Dr. sweden, S Africa, Scotland , England, Greece, EtcSeveral Hon Fellowships. Res Int Obs; gyn; fetal growth,preterm labour, Etc.

Civil Hons.. Awarded Knighthood ( Sir Naren ) 1997, forServices to Medicine; Made A Life Peer; seat in House ofLords Baron Patel of Dunkeld ( Lord Patel ) 1999.

Michael S. Paul, Ph.D.Dr. Paul has been involved in numerous biomedical technol-ogy start-up and licensing initiatives. Dr. Paul was Presidentand Chief Operating Officer at the non-profit LineaGenResearch Corporation, responsible for all corporate develop-ment and operational activities. Prior to joining LineaGenResearch Corporation, Dr. Paul worked for the start-upHuntsman Biotechnology Corporation as VP of BusinessDevelopment, and for the publicly-traded biopharmaceuti-cal company, NPS Pharmaceuticals, Inc. as Director of

Strategic Development.Dr. Paul has successfully led multidisci-

plinary product development teams, for-mulated strategic development initia-tives, and been responsible for thestrategic management of corporateintellectual property. At NPS, he wasinvolved in negotiations for severalmulti-million dollar licensing and corpo-rate acquisition deals. Dr. Paul has also

worked at the University of Utah Technology Transfer Office,where he has participated in marketing University inven-tions to the pharmaceutical and biotechnology industries.He is a licensed patent agent of the United States Patentand Trademark Office. Dr. Paul received his B.A. from ColbyCollege and his Ph.D. from the University of Utah.

Margaret Piper, Ph.D, MPHMargaret Piper, PhD, MPH is the Director of GenomicsResources at the Blue Cross and Blue Shield Association(BCBSA) Technology Evaluation Center (TEC,

www.bcbs.com/tec), an Agency for Healthcare Research andQuality (AHRQ)-funded Evidence-based Practice Center.She has been with TEC since 1994, joining the staff full-time in 1999. Her experience at TEC has focused on sys-tematic reviews of medical technology, including topics inautoimmunity and transplantation, oncology, laboratorymedicine, and genomics/genetic testing. Dr. Piper hasauthored over 30 TEC systematic reviews and reports andhas co-authored 4 AHRQ-EPC reports.

Among other outreach activities, Dr. Piper has served onthe Centers for Medicare and Medicaid Services’ MedicareEvidence Development & Coverage Advisory Committeeand on a work group for the Institute for Quality inLaboratory Medicine, and currently serves on the WorkingGroup for the CDC-funded Evaluation of GenomicApplications in Practice and Prevention (EGAPP) project.Roles of the EGAPP Working Group include: establishingmethods and process for evidence-based evaluation ofgenetic tests; prioritizing and selecting topics for review;participating in technical expert panels for commissionedevidence reviews;and developing conclusions or recommen-dations based on the evidence. In addition to these activi-ties, Dr. Piper has given presentations on evidence-basedevaluation of genetic tests at meetings organized by the

Institute of Medicine, Agency forHealthcare Research and Quality, andthe National Cancer Institute.

Prior experience includes over 13 yearsof managing a variety of clinical diag-nostic laboratory departments in bothacademic hospital and commercial clini-cal laboratory settings, designing andevaluating new laboratory diagnostics

for biomedical industry, consulting with physicians, publish-ing, and volunteer teaching for professional organizationsin laboratory medicine. In 2000, Dr. Piper received aDistinguished Service Award from the American Society ofClinical Pathologists Commission on Continuing Education.Following a mid-career National Cancer Institute fellowshipin cancer prevention and control, which included obtainingan MPH in epidemiology, Dr. Piper gained experience incancer epidemiology at the NCI and subsequently at theCenters for Disease Control and Prevention, with a focus oncancer genetics. Dr. Piper has a BS in molecular biology(University of Wisconsin—Madison), a PhD in immunology(Duke University), and an MPH in epidemiology (EmoryUniversity).

Aidan Power, MB BCh MSc MRCPsych Aidan Power is Vice President and Global Head ofMolecular Medicine at Pfizer. Molecular Medicine repre-sents a synthesis of all the emerging technologies (includ-ing imaging, pharmacogenomics, metabolomics and pro-teomics) that form the scientific basis of emergingapproaches to the development of Personalized Medicine.

Graduating in Medicine from University College Cork,


25

Ireland, Dr. Power trained as a psychiatrist in England,working mainly in clinical practice. He received post-gradu-ate qualifications in Psychiatry (MRCPsych) and the Historyof Science and Medicine (MSc) from University CollegeLondon and the Wellcome Institute for the History ofScience and Medicine.

In 1993, Dr. Power joined Pfizer in the United Kingdom atthe Sandwich Research and Development Laboratoriesworking on the antidepressant, Sertraline, and the antipsy-chotic, Ziprasidone. Aidan also set up a group at theresearch site in Clinical Pharmacogenetics.

In 2002, Dr. Power relocated to PfizerGlobal Research and DevelopmentHeadquarters in New London,Connecticut, where he headed ClinicalPharmacogenomics. In this role, he wasresponsible for developing the initialplan for the BioBank, a secure, long-term storage of DNA, biofluid and tissuesamples for use in exploratory research.This $17 million facility stores samples

at scale, using robotic systems that automate much of theisolation and storage of DNA, as well as apportioning andstorage of bio-fluids. Over the last year he has headed upMolecular Medicine which has been integrating molecularstudies across disease areas as well as developing diagnos-tics for critical programs in the Pfizer product pipeline.

Eiry Roberts, MB (Hons), BS, MRCP, FFPMDr. Roberts is a physician who trained in pharmacology andmedicine in the UK, qualifying from the University ofLondon in 1987. Her post-graduate clinical training was inclinical pharmacology and cardiology at St. Bartholomew’sHospital and the Royal London Hospital. She obtainedmembership of the Royal College of Physicians of the UK in1990.

In 1991 Dr. Roberts joined the Pharmaceutical Industry inthe UK working in clinical pharmacology and translationalclinical development. Her early career in the industryfocused on the exploratory clinical development of novelcardiovascular drugs, including antithrombotics andantiplatelet agents. Through this work she gained experi-ence in the application of established and novel biomarkersin early drug development.

Her last role at Lilly was Vice President ofProject/Program Medical. In this role she has responsibilityfor all Phase 1 and 2 clinical development across the 5therapeutic areas supported by Lilly. In addition all clinicaland translational biomarker efforts, including analyticalplatforms development, imaging, pharmacogenomics, pro-teomics, etc. fall within the scope of this Project/programMedical role. Recently, Eiry was promoted to Vice President,Transitional Phase Development.

Mollie Roth, Esq.With over 15 years in scientific research and the legal pro-fession, Mollie brings a unique combination of skills toDiaceutics focusing on the emerging market for personal-ized medicine. Based in the US, Mollie has combined herexperience as a research scientist with a complex pharma-ceutical liability legal practice to focus more recently on thepharmacolegal and regulatory environment surrounding thePersonalized Medicine industry and its evolving businessdynamic. Prior to joining the Diaceutics team, Mollieworked with Kaye Scholer LLP, New York, NY and NixonPeabody LLP, Washington, D.C. on behalf of a number ofpharmaceutical clients including Bayer, Novartis, Chiron,SmithKline Beecham and Pfizer.

Christine Seidman, MDChristine (Kricket) Seidman is a Professor in theDepartments of Medicine and Genetics at Harvard MedicalSchool and Brigham and Women’s Hospital. In 2005 shewas named the Thomas W. Smith Professor of Medicine.She is also an Investigator of the Howard Hughes MedicalInstitute. She was an undergraduate at Harvard Collegeand received a M.D. from George Washington UniversitySchool of Medicine in 1978. Dr. Seidman served as anintern and resident in Internal Medicine at John HopkinsHospital and received subspecialty training in cardiology atthe Massachusetts General Hospital. She joined the staff atBrigham and Women’s Hospital in 1987 and is currently theDirector of the Cardiovascular Genetics Center.

Honors include: Marion Hypertension Research Award(1984); American Heart Association Clinician-ScientistAward (1986); Bristol-Myers Squibb UnrestrictedCardiovascular Research Grant Award (1990); American

Heart Association EstablishedInvestigatorship Award (1992); Robert J.and Claire Pasarow Foundation Award inCardiovascular Research (1992);American Heart Association, EdgarHaber Cardiovascular Award (1997);American Heart Association, Helen B.Taussig Memorial Lecturer (1997);Member, Johns Hopkins University

Society of Scholars (1998); Member, American Academy ofArts and Sciences (1999); Member, Institutes of Medicine(1999); American Heart Association, Basic Research Prize(1999); Gill Heart Institute Award for CardiovascularResearch (2000); American College of Cardiology, Louis F.Bishop Lecture (2000); Gill Heart Institute Award forCardiovascular Research (2001); 12th Annual Bristol-MyersSquibb Award for Distinguished Achievement inCardiovascular Research (joint recipient with JonathanSeidman, PhD) (2002); Fellow, International Society HeartResearch (2002); Distinguished Scientist, American HeartAssociation (2003); Cannon Award, American PhysiologicSociety (2004); Member, Association of University

continued



26

Cardiologists (2005); Distinguished Alumni AchievementAward, The George Washington University (2005); Member,National Academy of Sciences (2005); Lefoulon-DelalandeFoundation, Grand Prix for Science (joint recipient withJonathan Seidman, PhD)(2007).

Dietrich Stephan, Ph.D.Dr. Stephan is chairman of the National Institutes of Health(NIH) Neuroscience Microarray Consortium, and has previ-ously held faculty appointments at Johns Hopkins

University, the National Human GenomeResearch Institute of the NIH, theUniversity of Arizona, Arizona StateUniversity, George WashingtonUniversity and the Children's NationalMedical Center in Washington, D.C.

Dr. Stephan has published extensivelyin journals such as Science, theProceedings of the National Academy ofSciences, Nature Genetics and the New

England Journal of Medicine. Dr. Stephan received his B.S.at Carnegie-Mellon University and his Ph.D. at theUniversity of Pittsburgh, and trained as a fellow at theNational Human Genome Research Institute of the NIH.

Steven St. Peter, M.D., MBADr. Steven St. Peter joined MPM in 2004 with experiencefrom Apax Partners and The Carlyle Group, where his invest-ment scope included both venture and buyout transactionsacross medical technology and pharmaceuticals. He beganworking at MPM in 2003 and was promoted to GeneralPartner in 2005. Dr. St. Peter was previously an assistantClinical Professor of Medicine at Columbia University. Hecompleted his Doctor of Medicine at Washington Universityand his residency and fellowship at the Hospital of theUniversity of Pennsylvania. Prior to his medical training, hewas an investment banker at Merrill Lynch. He also holdsan M.B.A. from the Wharton School of the University ofPennsylvania and a B.A. in Chemistry from the University ofKansas. He is on the Board of the New England VentureCapital Association.

Robert Tepper, M.D.Bob is an experienced scientific andmedical entrepreneur. Bob was presidentof R&D and CSO at Millennium. Bobalso co-founded Cell Genesys/Abgenix.He is a trained oncologist and molecularbiologist, an adjunct professor atHarvard Medical School and an advisoryboard member of several leading healthcare institutions.

Peter G. Traber, M.D.Peter G. Traber, MD, is president, CEO and executive dean ofBaylor College of Medicine.

Under Dr. Traber’s leadership, Baylor College of Medicineis building an innovative culture, healthcare campus, andmodel of care from the ground up for the delivery of per-sonalized medicine, using each patient’s unique genetic andmolecular profile to better prevent, predict and treat dis-ease. In 2007, Baylor College of Medicine broke ground ona 21st century healthcare facility that will integrate patient

care, research and education as neverbefore, while leveraging the College’srenowned strengths in research, science,and genomic medicine.

A recognized thought leader in aca-demic medicine, Dr. Traber serves on theDepartment of Veterans Affairs GenomicMedicine Program Advisory Committee,the Personalized Medicine Coalition,and the boards of BioHouston, BCM

Technologies, the Houston Technology Center, and theNational Space Biomedical Research Institute. He recentlyshared his vision for personalized medicine at the BurrillAnnual Personalized Medicine Meeting, the NationalCancer Institute’s caBIG™ Summit and Annual Meetingand HP’s Annual Life Sciences Conference.

Previously he was CEO of the University of PennsylvaniaHealth System and senior vice president and chief medicalofficer at GlaxoSmithKline.

He earned his MD at Wayne State University School ofMedicine in 1981 and completed a residency and fellow-ship at Northwestern University Medical School.

Scott T. Weiss, M.D., M.S.Dr. Weiss is currently Director of the Center for GenomicMedicine and Associate Director, Channing Laboratory, andProfessor of Medicine at Harvard Medical School. In thiscapacity, he leads a 25 investigator, 110 person researchgroup examining the environmental and genetic risk factorsfor the development of asthma and COPD.

He has authored or coauthored over 500 publicationsand three books in the area of asthma and COPD risk fac-tors and natural history. His initial work concerned the roleof airways responsiveness and environmental tobaccosmoke exposure in asthma and COPD, the effect of allergenexposure and airways responsiveness on markers of inflam-mation and the combined effect of these factors on thedevelopment of COPD. In 1996, he developed a stronginterest in the genetics of asthma and his recent work hasfocused on this, and novel exposures such as vitamin D andthe bowel flora. His laboratory is the only laboratory in theworld that has active NIH research in the areas of asthmagenetics, asthma pharmacogenetics, and COPD genetics. He


is the principal investigator or co-investigator on a total ofsix separate NHLBI-funded grant proposals in the area ofthe genetics of asthma and Asthma Pharmacogenetics,including a MERIT award.

Dr. Weiss has international research experience in China,The United Kingdom, Norway, Mexico, Costa Rica, and theNetherlands. Dr. Weiss is Principal Investigator of a longstanding T-32 Training grant (HL-07427). Dr Weiss has had27 trainees in the last 15 years, 25 of whom are still in aca-demic medicine. He has served as ATS assembly chair forthe EOH assembly and has served on numerous ATS com-mittees. He has served in an administrative capacity withthe NHLBI including the Special Emphasis Panel on the Useof NHLBI Specimens, the Oversight Committee for theCollaborative Study on the Genetics of Asthma, the NHLBIGenotyping Service Study Section, the T-32 review studysection, and the oversight committee for the NHLBI rese-quencing and genotyping facility.

Robert WellsRobert Wells has more than twenty years experience ingovernment relations, pubic policy and international corpo-rate development. His diverse career has given him expert-ise in business and policy issues associated with life sci-ences, health care, financial services and global markets.

Prior to co-founding HealthFutures, Robert served forseven years with Affymetrix, Inc, the world leader inmicroarray technology, as Vice President for CorporateAffairs and International Markets. In that role, he directedthe company’s internationally respected government rela-tions program, believed by many to be the most forwardthinking in the life sciences and health care industry. Robertsought not only to represent the company’s commercial andregulatory interests, but to open a wider dialogue with thepatients, payers, researchers, clinicians, ethicists, legalexperts, investors and other stake holders in the modernhealthcare ecosystem.

Robert is a founding member of the PersonalizedMedicine Coalition; he also played an industry role in theeffort to enact greater federal privacy protection for geneticinformation and drove an international dialogue on innova-tive intellectual property regimes. Working in corporatedevelopment, he launched a successful business strategy toenter the China market and started innovative collabora-tions with world class research centers in Sweden, France,Singapore and Korea.

Before joining Affymetrix, Robert had a highly successfulcareer with Citigroup where he served as Vice President forInternational Government Relations, coordinating pubic pol-icy efforts in the company’s almost-100 overseas offices. Hehas also taken time from his traditional career path to workin three presidential campaigns and to write two televisionpilots for Columbia/Tri-Star Television.

Robert completed his undergraduate work at theUniversity of North Carolina / Chapel Hill. He also holds aJD degree from the Wake Forest University School of Law.He is a member of the Board of Directors of thePersonalized Medicine Coalition and chairs the organiza-tion’s Public Policy Committee. He has been a frequentspeaker before various professional groups.

27



28



30

Great Innovations Deserve Great PartnershipsWe can’t do our jobs without you. At Applied Biosystems our Business Development Group knows the value that can

be created when private or academic innovators leverage the strengths of a premier life science organization to bring

their ideas to market. Companies like BG Medicine, GenCO, Ambion and Agencourt have already taken advantage

of an affiliation with Applied Biosystems. If you are interested in exploring a potential life science R&D or marketing

collaboration, a licensing opportunity, or the sale of your company, our Business Development team wants to meet you.

For more information email [email protected]

HBS_Ad_08.indd 1 10/20/08 1:28:52 PM

31

©2008 Aetna Inc.

Aetna is proud to be a sponsor of the Harvard Medical School – Partners HealthCare Center for Genetics and Genomics Personalized Medicine: A Value Proposition Conference

Helping Members Achieve Optimal Health

We want

you to know®



32

33

POST-CONFERENCECOVERAGE

After the conference, find keynote

presentations,summary articles, press coverage,

photographsand more at:

www.hpcgg.org/PM/2008



34

LABORATORY FOR MOLECULAR MEDICINE

A diagnostics laboratory created by

Bringing genetics to medicine

HARVARD MEDICAL SCHOOL – PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

HARVARD MEDICAL SCHOOL-PARTNERS HEALTHCARE CENTER FOR GENETICS AND GENOMICS

Interim Scientific Director: Scott Weiss, M.D., Professor of Medicine, HarvardMedical School, Brigham and Women's Hospital

To realize the promise of genetics and genomics in research and in medical practice,Harvard Medical School and Partners HealthCare System established the HarvardMedical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) in2001. Its mission is to accelerate personalized medicine by discovering genetic knowl-edge and integrating it into clinical medicine. The availability of the human genomesequence and the many high throughput technologies that have been developed haveenabled an extraordinary growth in the identification of genes and of the specific geneticchanges that are responsible for human disease. Widespread use of genetic and genomicinformation will revolutionize medical practice. It is anticipated that genetic and genom-ic testing will become an integral part of diagnosis, prognosis and treatment of diseaseand in determining the appropriate drugs for individual patients.

HPCGG is accomplishing its mission through the following approaches:• Recruiting outstanding physicians and scientists• Offering genetic-based diagnostic testing and developing new tests in its

Laboratory for Molecular Medicine• Developing and implementing strategies for evaluating the clinical outcomes of

incorporating genetics into clinical practice• Developing an IT infrastructure to integrate genetic and genomic data into

clinical decision support systems• Caring for patients with genetic disorders• Training and educating physicians, scientists and the public

For more information about the Center, please visit www.hpcgg.org.

HARVARD BUSINESS SCHOOLHarvard Business School’s mission is to train business leaders in all industries.Healthcare, a $2 trillion industry, has become one of the school’s key priorities. TheHealthcare Initiative at HBS was launched in 2005 to bring together the extensiveresearch, thought leadership, and interest in the business and management of healthcarethat exists at HBS.

Healthcare research at HBS focuses on entrepreneurship, innovation and disruption.Faculty and students seek to understand and identify new products, services and deliverymethods that will help to reshape the industry. HBS believes this focus on “creativedestruction” will result in business models that offer the hope of improved outcomes,reduced costs, streamlined systems, and enhanced services.

Personalized medicine presents tremendous opportunities in healthcare and has garneredmuch attention at HBS. With its expertise in technology, commercialization, and busi-ness model development, HBS can play a critical role in the widespread adoption of per-sonalized medicine applications.

For more information about the HBS Healthcare Initiative, please visitwww.hbs.edu/healthcare.

HARVARD MEDICAL SCHOOL-PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

77 Avenue Louis PasteurNRB Suite 250

Boston, MA 02115

[email protected]

Personalized Medicine: A Value Proposition

Conference staffHarvard Medical School-Partners HealthCare Center for Genetics and Genomics

Alfred A. Blum, Jr.Chief Development Officer

[email protected]

Janice LarsonDevelopment [email protected]

Rebecca RehmProgram Associate

[email protected]

Meini Sumbada ShinAdministrative Director

[email protected]

Personalized Medicine...the aspiration that personalized medicine can and will be the paradigm for...

Documents

Transcript of Personalized Medicine...the aspiration that personalized medicine can and will be the paradigm for...